XML 71 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 6 Months Ended
Dec. 31, 2019
Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) attributable to Myriad Genetics, Inc. stockholders $ (28.9) $ 1.9
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 36.4 36.3
Non-cash interest expense 0.2 (1.2)
Loss on disposition of assets (0.1) (0.9)
Share-based compensation expense 15.8 15.2
Deferred income taxes (6.8) 2.3
Unrecognized tax benefits 0.7 (2.3)
Impairment of goodwill classified as held for sale 1.3  
Change in fair value of contingent consideration 0.7 (1.4)
Changes in assets and liabilities:    
Prepaid expenses (0.2) 0.8
Trade accounts receivable 13.6 (0.9)
Other receivables (0.3) (1.9)
Inventory 2.6 6.1
Prepaid taxes 0.4 (3.1)
Accounts payable (11.3) (0.3)
Accrued liabilities (11.8) (4.7)
Deferred revenue 1.6 (0.3)
Net cash provided by operating activities 13.9 45.6
CASH FLOWS FROM INVESTING ACTIVITIES    
Capital expenditures (4.8) (4.1)
Acquisitions, net of cash acquired   (278.5)
Purchases of marketable investment securities (45.0) (36.6)
Proceeds from maturities and sales of marketable investment securities 35.5 32.1
Net cash used in investing activities (14.3) (287.1)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds from common stock issued under share-based compensation plans 1.3 4.5
Payment of contingent consideration recognized at acquisition (3.9)  
Net proceeds from revolving credit facility   340.0
Repayment of revolving credit facility (8.6) (75.0)
Repurchase and retirement of common stock   (50.0)
Net cash provided by (used in) financing activities (11.2) 219.5
Effect of foreign exchange rates on cash and cash equivalents 1.1 1.7
Change in cash and cash equivalents classified as held for sale (1.5)  
Net decrease in cash and cash equivalents (12.0) (20.3)
Cash and cash equivalents at beginning of the period 93.2 110.9
Cash and cash equivalents at end of the period $ 81.2 $ 90.6